scispace - formally typeset
E

Eugene Braunwald

Researcher at Brigham and Women's Hospital

Publications -  1758
Citations -  278949

Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

Effect of respiration on venous return and stroke volume in cardiac tamponade

TL;DR: Findings point to competition for space by the ventricles in the distended pericardial sac as being the major factor in the production of pulsus paradoxus.
Journal ArticleDOI

The krypton85 inhalation test for the detection of left-to-right shunts.

TL;DR: Radioactive krypton (Kr85) has been found to provide substantial advantages over other gases and it has therefore been employed routinely in this laboratory for the past several years and it is the purpose of this communication to analyse the results obtained from the application of the Kr85 inhalation test in 323 patients.
Journal ArticleDOI

Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial

TL;DR: A biomarker-based strategy identifies a gradient of risk among patients post-ACS, offering the potential to identify higher-risk patients with a correspondingly high absolute benefit from the addition of ezetimibe to statin therapy.
Journal ArticleDOI

Effects of acutely induced ischemic heart failure on myocardial high energy phosphate stores.

TL;DR: The results indicate that acute ischemic heart failure is not initiated by a detectable depression in total myocardial ATP stores, and this should not be interpreted as a cause for concern.
Journal ArticleDOI

Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II).

TL;DR: The increased mortality rate with bypass surgery after thrombolytic therapy, particularly in patients undergoing operation within 24 h of coronary angioplasty or during the involving phase of infarction, must be balanced against the excellent 1-year prognosis and perioperative survivors, who are in general a group at higher risk of death or recurrent infarctions.